OFIX - オ―ソフィックス・インタ―ナショナル （Orthofix Medical Inc. ） オ―ソフィックス・インタ―ナショナルOFIXのチャート
OFIXの企業情報
| symbol | OFIx |
|---|---|
| 会社名 | Orthofix International N.V. （オ―ソフィックス・インタ―ナショナル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 オーソフィックス・インターナショナル(Orthofix International N.V.)はグローバルな医療機器会社であり、再建・再生の整形外科および脊椎手術を医師に提供する。同社は4つの事業を運営する。BioStimソリューション製品には、子宮頸部 - スティム、脊柱 - スティム及びフィジオ - スティムが含まれる。生物製剤製品には、AlloQuent構造同種移植、Trinity ELITE、Trinity Evolution、VersaShieldが含まれている。下肢固定製品には、固定具、8枚ガイド付き成長システム及びContours VPS Volar Plating System IIIがある。脊椎固定製品には、正面前頸椎プレートシステム、前後背骨後頸部胸腺（POCT）システム、火鳥変形矯正システム、フェニックス最小侵襲脊柱固定システム、サンバスクリューシステム、LONESTAR子宮頸部スタンドアロン（CSA）、SKYHAWK側面 椎体間癒合システムおよび側方プレートシステムおよびCENTURION POCTシステムが含まれる。 オ―ソフィックス・インタ―ナショナルは、オランダ領アンティル諸島籍の医療機器メ―カ―。脊椎及び整形外科市場への治療・再生ソリュ―ションの開発、生産、販売を中心に事業を展開。主な製品は、外部固定装置「Orthofix」、偽関節骨折の治療効果を高める「Spinal Stim」、超音波骨セメント除去システム「Oscar」など。 Orthofix Medical Inc. is a global medical device and biologics company with a spine and extremities focus. The Company's mission is to deliver innovative, quality-driven solutions as it partners with health care professionals to improve patients' lives. Headquartered in Lewisville, Texas, Orthofix's spine and orthopedic extremities products are distributed in more than 70 countries via the Company's sales representatives and distributors. |
| 本社所在地 | 7 Abraham de Veerstraat Curacao ANT |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 214-937-2000 |
| 設立年月日 | 32051 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1992年 |
| 従業員数 | 858人 |
| url | www.orthofix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ofix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 60.39100 |
| 終値（lastsale） | 56.56 |
| 時価総額（marketcap） | 1069603275.44 |
| 時価総額 | 時価総額（百万ドル） 173.575 |
| 売上高 | 売上高（百万ドル） 442.39900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 127.889 |
| 当期純利益 | 当期純利益（百万ドル） 18.87300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Orthofix Medical Inc revenues increased 4% to $220.3M. Net income before extraordinary items increased from $2.4M to $5.7M. Revenues reflect BioStim segment increase of 100% to $94.4M Extremity Fixation segment increase from $24.7M to $51.4M Biologics segment increase from $15.7M to $39.1M. Net income benefited from BioStim segment income increase from $19.5M to $40.2M. |
OFIXのテクニカル分析
OFIXのニュース
These strategies will help Orthofix Medical Inc. (OFIX) succeed 2022/12/02 16:48:00 US Post News
Orthofix Medical Inc. (NASDAQ:OFIX) closed Thursday at $19.87 per share, up from $17.99 a day earlier. While Orthofix Medical Inc. has overperformed by 10.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OFIX fell by -35.36%, with highs and lows ranging from $36.12 to $13.76, whereas […]
Orthofix Medical stock gains after receiving $23/share takeover offer from PE firms 2022/12/01 01:05:26 Seeking Alpha
Orthofix Medical (OFIX) rose 7.3% after disclosing it received an unsolicited takeover interest from two private equity firms for $23/share in cash.Orthofix (OFIX) said it received…
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, KNBE, IMRA, LFG 2022/11/15 15:55:00 PR Newswire
NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Orthofix Medical Inc. (NASDAQ: OFIX)''s…
Orthofix Medical Announces Participation in Upcoming Stifel Healthcare Conference 2022/11/10 12:00:00 Business Wire
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Stifel 2022 Healthcare investor conference on Wednesday, November 16, 2022 at 8:00 a.m. ET. The conference will be held live at the Lotte New York Palace in NYC and one-on-one meetings will b
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, FORG, LFG, IMRA 2022/11/06 18:09:59 Benzinga
NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Orthofix Medical Inc. (NASDAQ: OFIX )''s merger with SeaSpine Holdings Corporation. Following the close of the transaction, Orthofix shareholders will own approximately 56.5% of the combined company. If you are an Orthofix shareholder, click here to learn more about your rights and options . ForgeRock, Inc. (NYSE: FORG )''s sale … Full story available on Benzinga.com
Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures 2022/10/13 11:00:00 Wallstreet:Online
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis or extremities. Legacy DBM is processed by MTF Biologics, leveraging decades of experience through
Orthofix stock falls amid SeaSpine merger despite rise in prelim Q3 revenue 2022/10/11 11:29:52 Seeking Alpha
Orthofix Medical (OFIX) preliminary Q3 revenue results $114M, which is seen above analysts estimates, amid a merger announcement with SeaSpine (SPNE).The company said the projected…
SeaSpine prelim Q3 revenue seen above estimates, raises FY22 outlook amid Orthofix merger 2022/10/11 10:59:51 Seeking Alpha
SeaSpine (SPNE) reported preliminary Q3 revenue results, which is seen above analysts'' estimates, raised its FY22 outlook amid announcement of a merger with Orthofix Medical (OFIX).As…
SeaSpine soars 15% on all-stock merger with Orthofix 2022/10/11 10:35:37 Seeking Alpha
Lewisville, Texas.-based Orthofix Medical (OFIX) and Carlsbad, Calif.-based SeaSpine (SPNE) are merging in an all-stock transaction.Under the agreement, SeaSpine shareholders will…
Orthofix Medical Inc.: Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company 2022/10/11 10:03:00 Finanz Nachrichten
Highly complementary spine and orthopedics portfolios One of the industry''s broadest biologics and regenerative technology offerings Differentiated and synergistic enabling technologies Meaningful…
The Global Orthopedic Trauma Devices Market is Anticipated to Surge at a CAGR of 6.41% Reaching USD 10.08 Billion by 2026, Analyzes DelveInsight 2022/05/05 17:00:00 Benzinga
New York, USA, May 05, 2022 (GLOBE NEWSWIRE) -- The Global Orthopedic Trauma Devices Market is Anticipated to Surge at a CAGR of 6.41% Reaching USD 10.08 Billion by 2026, Analyzes DelveInsight The Orthopedic Trauma Devices market is expected to boost owing to the rising incidence of trauma and accident cases, the increasing prevalence of degenerative bone disorders, the increasing number of sports-related injuries, rising technological advancements pertaining to orthopedic trauma devices, and the rising number of new product launches, among others. According to the latest report published by DelveInsight, " Orthopedic Trauma Devices Market Insight Report ," the global Orthopedic Trauma Devices market is expected to witness significant growth owing to an increase in the prevalence of simple fractures and severe life-threatening injuries. Furthermore, the rising number of accidents or other fatal incidences, along with the rising number of trauma associated with road accidents, fall injuries, and the increasing prevalence pertaining to osteoarthritis and orthopedic sports injury, is also a major factor contributing to the growth of Orthopedic Trauma Devices market.
Orthofix Medical Schedules First Quarter Earnings Release and Conference Call for May 6, 2022 2022/04/28 11:00:00 Business Wire
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the first quarter 2022 before market open on Friday, May 6, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 8:30 a.m. ET the same day. Interested parties may access the
Bone Growth Stimulators Market to Progress at a Substantial CAGR of 5.34% by 2026, as per DelveInsight''s Analysis 2022/04/12 17:00:00 Benzinga
Las Vagas, USA, April 12, 2022 (GLOBE NEWSWIRE) -- Bone Growth Stimulators Market to Progress at a Substantial CAGR of 5.34% by 2026, as per DelveInsight''s analysis The Bone Growth Stimulators market is witnessing a positive market growth owing to the factors such as the prevalence of degenerative bone-related disorders, increasing cases of accident and traumatic cases such as road crashes, sports injuries, and the accumulative focus on developing technologically advanced devices with respect to Bone Growth Stimulators. DelveInsight''s Bone Growth Stimulators Market Insights and Forecast report provides the current and forecast Bone Growth Stimulators Market, upcoming innovations in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Bone Growth Stimulators Market. Some of the essential factors from the Bone Growth Stimulators Market report: As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth and occupy the largest share in the Bone Growth Stimulators market.